MX391149B - Vacunas contra el virus de inmunodeficiencia humana (vih) que comprenden uno o mas antigenos episensus de poblacion. - Google Patents
Vacunas contra el virus de inmunodeficiencia humana (vih) que comprenden uno o mas antigenos episensus de poblacion.Info
- Publication number
- MX391149B MX391149B MX2017004275A MX2017004275A MX391149B MX 391149 B MX391149 B MX 391149B MX 2017004275 A MX2017004275 A MX 2017004275A MX 2017004275 A MX2017004275 A MX 2017004275A MX 391149 B MX391149 B MX 391149B
- Authority
- MX
- Mexico
- Prior art keywords
- hiv
- vaccine
- antigen
- subject
- epigraph
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/867—Retroviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16141—Use of virus, viral particle or viral elements as a vector
- C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462059497P | 2014-10-03 | 2014-10-03 | |
| US201462059506P | 2014-10-03 | 2014-10-03 | |
| PCT/US2015/054067 WO2016054654A1 (en) | 2014-10-03 | 2015-10-05 | Hiv vaccines comprising one or more population episensus antigens |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017004275A MX2017004275A (es) | 2018-01-17 |
| MX391149B true MX391149B (es) | 2025-03-21 |
Family
ID=55631703
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017004275A MX391149B (es) | 2014-10-03 | 2015-10-05 | Vacunas contra el virus de inmunodeficiencia humana (vih) que comprenden uno o mas antigenos episensus de poblacion. |
| MX2022003663A MX2022003663A (es) | 2014-10-03 | 2017-03-31 | Vacunas contra el virus de inmunodeficiencia humana (vih) que comprenden uno o mas antigenos episensus de poblacion. |
| MX2022003664A MX2022003664A (es) | 2014-10-03 | 2017-03-31 | Vacunas contra el virus de inmunodeficiencia humana (vih) que comprenden uno o mas antigenos episensus de poblacion. |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022003663A MX2022003663A (es) | 2014-10-03 | 2017-03-31 | Vacunas contra el virus de inmunodeficiencia humana (vih) que comprenden uno o mas antigenos episensus de poblacion. |
| MX2022003664A MX2022003664A (es) | 2014-10-03 | 2017-03-31 | Vacunas contra el virus de inmunodeficiencia humana (vih) que comprenden uno o mas antigenos episensus de poblacion. |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10894078B2 (enExample) |
| EP (1) | EP3200878B1 (enExample) |
| JP (3) | JP2017531693A (enExample) |
| KR (1) | KR102633096B1 (enExample) |
| CN (1) | CN108064181A (enExample) |
| AU (2) | AU2015327797A1 (enExample) |
| CA (1) | CA2963573C (enExample) |
| EA (1) | EA201790680A1 (enExample) |
| HK (1) | HK1254806A1 (enExample) |
| IL (1) | IL251469B2 (enExample) |
| MA (1) | MA40783A (enExample) |
| MX (3) | MX391149B (enExample) |
| SG (1) | SG11201702729YA (enExample) |
| UA (1) | UA126890C2 (enExample) |
| WO (1) | WO2016054654A1 (enExample) |
| ZA (1) | ZA202206809B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA40783A (fr) | 2014-10-03 | 2017-08-08 | Los Alamos Nat Security Llc | Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population |
| JP6890831B2 (ja) | 2015-07-08 | 2021-06-18 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | Ｈｉｖ予備免疫化および免疫療法 |
| JP7153332B2 (ja) | 2016-02-08 | 2022-10-14 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | Ｈｉｖワクチン接種および免疫療法 |
| WO2018009246A1 (en) | 2016-07-08 | 2018-01-11 | American Gene Technologies International Inc. | Hiv pre-immunization and immunotherapy |
| WO2020243485A1 (en) * | 2019-05-29 | 2020-12-03 | Massachusetts Institute Of Technology | Hiv-1 specific immunogen compositions and methods of use |
| JP7454645B2 (ja) | 2019-07-16 | 2024-03-22 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖワクチン並びにその作製方法及び使用方法 |
| PH12022550490A1 (en) | 2019-08-29 | 2023-02-06 | Triad Nat Security Llc | Hepatitis b virus vaccines |
| JP7693813B2 (ja) | 2021-01-14 | 2025-06-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖワクチン及び使用方法 |
| US20240384296A1 (en) | 2021-08-31 | 2024-11-21 | Vir Biotechnology, Inc. | Recombinant hcmv vectors and uses thereof |
| TW202436326A (zh) * | 2023-02-13 | 2024-09-16 | 長怡 王 | 包含hiv th/ctl 抗原決定位胜肽的疫苗用於預防及治療hiv感染及aids患者 |
| CN116524994A (zh) * | 2023-02-20 | 2023-08-01 | 中国科学院天津工业生物技术研究所 | 一种基于贪婪算法的菌株构建排程设计方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI116851B (fi) * | 2001-05-03 | 2006-03-15 | Fit Biotech Oyj Plc | Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita |
| BR0212619A (pt) | 2001-09-20 | 2004-08-17 | Glaxo Group Ltd | Sequência de nucleotìdeo, vetor, proteìna, composição farmacêutica, dispositivo de liberação intradérmica, método para tratar um paciente que sofre de uma doença ou é suscetìvel a ela, uso de uma sequência de nucleotìdeo, e, processo para a produção de um nucleotìdeo |
| AUPR842501A0 (en) * | 2001-10-23 | 2001-11-15 | Epipop Pty Ltd | A method for identification and development of therapeutic agents |
| US20030190308A1 (en) * | 2002-03-19 | 2003-10-09 | Braun Ralph P. | Adjuvant |
| GB0225788D0 (en) * | 2002-11-05 | 2002-12-11 | Glaxo Group Ltd | Vaccine |
| EP1609107A4 (en) * | 2003-03-28 | 2006-08-30 | Idm Pharma Inc | METHOD FOR IDENTIFYING OPTIMAL PEPTIDE PITOPARIANTS |
| CN1852734B (zh) | 2003-09-17 | 2010-12-01 | 杜克大学 | 共有/祖先免疫原 |
| AU2011203095A1 (en) | 2003-09-17 | 2011-07-21 | Duke University | Consensus/Ancestral Immunogens |
| NZ547042A (en) | 2003-10-10 | 2010-05-28 | Powderject Vaccines Inc | Method for eliciting a T-cell response |
| EP1766096B1 (en) | 2004-05-25 | 2013-01-02 | Oregon Health and Science University | Hiv vaccination usingand hcmv-based vaccine vectors |
| WO2007024941A2 (en) * | 2005-08-23 | 2007-03-01 | The Regents Of The University Of California | Polyvalent vaccine |
| KR102511874B1 (ko) | 2006-07-28 | 2023-03-20 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 개선된 백신 및 이의 사용 방법 |
| US20110123485A1 (en) * | 2007-03-27 | 2011-05-26 | President And Fellows Of Harvard College | Viral vectors for delivering vaccines for hiv and other infectious diseases |
| US20100183651A1 (en) * | 2007-03-30 | 2010-07-22 | Finnefrock Adam C | Broadly Representative Antigen Sequences and Method for Selection |
| SMT201800631T1 (it) | 2008-11-18 | 2019-01-11 | Beth Israel Deaconess Medical Ct Inc | Vaccini antivirali con immunogenicità cellulare migliorata |
| KR20120093941A (ko) * | 2009-10-08 | 2012-08-23 | 버베리안 노딕 에이/에스 | 인간에서 ｈｉｖ에 대한 광범위한 ｔ-세포 반응의 생성 |
| EP2550362B1 (en) | 2010-03-25 | 2017-01-04 | Oregon Health&Science University | Cmv glycoproteins and recombinant vectors |
| WO2011143653A2 (en) | 2010-05-14 | 2011-11-17 | Oregon Health & Science University | Recombinant hcmv and rhcmv vectors and uses thereof |
| US8557787B2 (en) | 2011-05-13 | 2013-10-15 | The Board Of Trustees Of The Leland Stanford Junior University | Diagnostic, prognostic and therapeutic uses of long non-coding RNAs for cancer and regenerative medicine |
| PT2691530T (pt) | 2011-06-10 | 2018-05-10 | Univ Oregon Health & Science | Glicoproteínas e vectores recombinantes cmv |
| EP2620446A1 (en) | 2012-01-27 | 2013-07-31 | Laboratorios Del Dr. Esteve, S.A. | Immunogens for HIV vaccination |
| ES2718899T3 (es) | 2012-03-02 | 2019-07-05 | Us Gov Health & Human Services | Método para modificar la jerarquía de inmunodominio de gag del VIH mediante una vacuna de ADN que expresa regiones conservadas |
| EP2983686B1 (en) * | 2013-01-07 | 2024-05-29 | Beth Israel Deaconess Medical Center, Inc. | Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same |
| PL2964769T3 (pl) * | 2013-03-05 | 2019-03-29 | Oregon Health & Science University | Wektory cytomegalowirusa umożliwiające kontrolę ukierunkowania limfocytów T |
| CA2941116A1 (en) | 2014-02-28 | 2015-09-03 | Janssen Vaccines & Prevention B.V. | Replicating recombinant adenovirus vectors, compositions, and methods of use thereof |
| AU2015289560B2 (en) | 2014-07-16 | 2018-09-27 | Oregon Health & Science University | Human cytomegalovirus comprising exogenous antigens |
| EA202092521A1 (ru) | 2014-09-26 | 2021-05-31 | Бет Изрейэл Диконисс Медикал Сентер, Инк. | Способы и композиции для индукции защитного иммунитета против инфекции вирусом иммунодефицита человека |
| MA40783A (fr) | 2014-10-03 | 2017-08-08 | Los Alamos Nat Security Llc | Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population |
| TWI792091B (zh) | 2015-12-15 | 2023-02-11 | 荷蘭商傑森疫苗防護公司 | 人類免疫缺陷病毒抗原、載體、組成物、及其使用方法 |
-
2015
- 2015-10-04 MA MA040783A patent/MA40783A/fr unknown
- 2015-10-05 US US15/516,491 patent/US10894078B2/en active Active
- 2015-10-05 CA CA2963573A patent/CA2963573C/en active Active
- 2015-10-05 MX MX2017004275A patent/MX391149B/es unknown
- 2015-10-05 IL IL251469A patent/IL251469B2/en unknown
- 2015-10-05 SG SG11201702729YA patent/SG11201702729YA/en unknown
- 2015-10-05 KR KR1020177012171A patent/KR102633096B1/ko active Active
- 2015-10-05 HK HK18113892.2A patent/HK1254806A1/zh unknown
- 2015-10-05 EA EA201790680A patent/EA201790680A1/ru unknown
- 2015-10-05 UA UAA201704021A patent/UA126890C2/uk unknown
- 2015-10-05 JP JP2017538177A patent/JP2017531693A/ja active Pending
- 2015-10-05 CN CN201580063643.3A patent/CN108064181A/zh active Pending
- 2015-10-05 EP EP15847978.2A patent/EP3200878B1/en active Active
- 2015-10-05 WO PCT/US2015/054067 patent/WO2016054654A1/en not_active Ceased
- 2015-10-05 AU AU2015327797A patent/AU2015327797A1/en not_active Abandoned
-
2017
- 2017-03-31 MX MX2022003663A patent/MX2022003663A/es unknown
- 2017-03-31 MX MX2022003664A patent/MX2022003664A/es unknown
-
2020
- 2020-08-31 US US17/008,289 patent/US11628215B2/en active Active
- 2020-08-31 US US17/008,335 patent/US11554168B2/en active Active
- 2020-10-09 JP JP2020170852A patent/JP7212020B2/ja active Active
-
2021
- 2021-08-19 AU AU2021218141A patent/AU2021218141B2/en active Active
-
2022
- 2022-06-20 ZA ZA2022/06809A patent/ZA202206809B/en unknown
-
2023
- 2023-01-12 JP JP2023003194A patent/JP7441340B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX391149B (es) | Vacunas contra el virus de inmunodeficiencia humana (vih) que comprenden uno o mas antigenos episensus de poblacion. | |
| CY1124867T1 (el) | Αντισωματα μονης περιοχης που κατευθυνονται εναντι ενδοκυτταρικων αντιγονων | |
| MX2017008186A (es) | Anticuerpos humanos para la hemaglutinina de influenza. | |
| PH12018501281A1 (en) | Human immunodeficiency virus neutralizing antibodies | |
| CL2017001920A1 (es) | Anticuerpos humanos contra glicoproteína del virus ébola | |
| MX2016011537A (es) | Metodos y composiciones para aumentar una relacion de celulas t efectoras con respecto a las celulas t reguladoras. | |
| NI201800052A (es) | Anticuerpos que neutraliza el virus respiratorio sincitial humano | |
| MX383596B (es) | Moleculas biespecificas que son inmunorreactivas con celulas efectoras inmunes que expresan un receptor activador y un antigeno expresado por una celula infectada por un virus y usos de las mismas. | |
| HUE045993T2 (hu) | Emberi immunhiány vírus antigének, vektorok, készítmények és alkalmazásukra szolgáló eljárások | |
| MX391015B (es) | Composiciones de nanoparticulas y usos de las mismas | |
| MX2018010586A (es) | Nanovacuna de activacion de "sting" para inmunoterapia. | |
| MX384422B (es) | Vector que expresa conjuntamente vacunas y moléculas coestimuladoras | |
| EA201790532A1 (ru) | Способы и композиции для ослабления иммунных ответов против вирусного вектора для переноса | |
| MX370191B (es) | Composiciones y su uso en el tratamiento de la inmunodeficiencia. | |
| NZ731659A (en) | Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus | |
| CU24580B1 (es) | Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas | |
| EA201892233A1 (ru) | Композиции и способы, связанные с иммуногенами вич-1 | |
| WO2016191641A3 (en) | Methods for enhancing antigen-specific immune responses using combination therapy comprising papillomavirus capsid antigens | |
| WO2016130560A3 (en) | Cross-reactive t cell epitopes of hiv, siv, and fiv for vaccines in humans and cats | |
| MX2019007924A (es) | Vacunas contra la influenza. | |
| IN2015DN03925A (enExample) | ||
| MX2017001649A (es) | Peptido derivado de koc1 y vacuna que lo incluye. | |
| MX2019006244A (es) | Construcciones de vectores virales para la expresion de adyuvantes geneticos que activan la ruta sting. | |
| BR112017002193A2 (pt) | peptídeo derivado de urlc10 e vacina contendo o mesmo | |
| BR112018005728A2 (pt) | epítopos de célula t de reatividade cruzada de hiv, siv e fiv para vacinas em humanos e gatos |